World-leading tissue proteomic services provider, ProCan Technologies has today launched the TargetQuantTM Antibody-Drug Conjugate (ADC) Panel at BIO2025 in Boston, USA. The panel is designed to support the development of ADCs across a wide range of cancers. Leveraging the capabilities and intellectual property developed within the ProCan program at Children’s Medical Research Institute in Sydney, Australia, […]
News
We are proud to announce some of the international leaders in medical research and clinical research joining the conference as international speakers panel at the ProCan Sydney International Conference: Advancing Multi-Omics into the Clinic. Prof Ruedi Abersold, a leader in Molecular Systems Biology at ETH Zürich. His pioneering work in mass spectrometry-based proteomics has reshaped […]
Congratulations to the ProCan® team on their latest publication. This research delves into the optimisation of proteomics and phosphoproteomic biomarker studies using formalin-fixed paraffin-embedded (FFPE) tissues. The team compared four methods to remove the wax and rehydrate these samples and evaluated five extraction methods to identify the most effective approaches for FFPE tissue analysis by […]
Join us in our ProCan Conference, ‘Advancing Multi-Omics into the Clinic’, Sydney – Australia, 18th-19th November 2024. Through this two-day meeting, internationally renowned experts in proteomics, genomics, cancer management, biomarker, and drug discovery will share their progress towards addressing the challenges and opportunities of multi-omic data integration in cancer management, with a special focus on […]